{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T00:04:49Z","timestamp":1648944289066},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"S3","license":[{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Adv Therapy"],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1007\/s12325-010-0109-3","type":"journal-article","created":{"date-parts":[[2011,3,23]],"date-time":"2011-03-23T01:05:01Z","timestamp":1300842301000},"page":"10-16","source":"Crossref","is-referenced-by-count":2,"title":["Acute myeloblastic leukemia"],"prefix":"10.1007","volume":"28","author":[{"given":"Carmen Avellaneda","family":"Molina","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Jos\u00e9 Requena","family":"Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nieves Somolinos","family":"de Marcos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Font","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,3,9]]},"reference":[{"key":"109_CR1","volume-title":"Prescribing information","author":"Vidaza\u00ae","year":"2008","unstructured":"Vidaza\u00ae (azacitidine for injection). Prescribing information. Summit, NJ: Celgene Corporation; August 2008. Available at: http:\/\/www.vidaza.com\/pdf\/PI_FINAL.pdf . Accessed January 25, 2011."},{"key":"109_CR2","unstructured":"Anexo I: Ficha t\u00e9cnica o resumen de las caracter\u00edsticas del producto [in Spanish]. Available at: http:\/\/www.ema.europa.eu\/docs\/es_ES\/document_library\/EPAR_-_Product_Information\/human\/000978\/WC500050239.pdf . Accessed January 25, 2011."},{"key":"109_CR3","unstructured":"National Institute of Cancer: Clinical Trials search results. Available at: http:\/\/www.cancer.gov\/search\/ResultsClinicalTrials.aspx?protocolsearchid=8723965 . Accessed January 25, 2011."},{"key":"109_CR4","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1200\/JCO.2002.04.117","volume":"20","author":"L.R. Silverman","year":"2002","unstructured":"Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol. 2002;20:2429\u20132440.","journal-title":"J Clin Oncol"},{"key":"109_CR5","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1200\/JCO.2002.04.044","volume":"20","author":"A.B. Kornblith","year":"2002","unstructured":"Kornblith AB, Herndon JE 2nd, Silverman LR, et al. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J Clin Oncol. 2002;20:2441\u20132452.","journal-title":"J Clin Oncol"},{"key":"109_CR6","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1200\/JCO.2005.05.4346","volume":"24","author":"L.R. Silverman","year":"2006","unstructured":"Silverman LR, McKenzie DR, Peterson BL, et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol. 2006;24:3895\u20133903.","journal-title":"J Clin Oncol"},{"key":"109_CR7","first-page":"21","volume":"7","author":"L.R. Silverman","year":"1993","unstructured":"Silverman LR, Holland JF, Weinberg RS, et al. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia. 1993;7:21\u201329.","journal-title":"Leukemia"},{"key":"109_CR8","first-page":"A12","volume":"68","author":"L.R. Silverman","year":"1994","unstructured":"Silverman LR, Holland JF, Demakos EP, et al. Azacitidine (Aza C) in myelodysplastic syndromes (MDS), CALGB studies 8421 and 8921. Ann Hematol. 1994;68:A12. Abstract 46.","journal-title":"Ann Hematol."},{"key":"109_CR9","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","volume":"10","author":"P. Fenaux","year":"2009","unstructured":"Fenaux P, Mufti G, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10:223\u2013232.","journal-title":"Lancet Oncol"},{"key":"109_CR10","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1200\/JCO.2009.23.8329","volume":"28","author":"P. Fenaux","year":"2009","unstructured":"Fenaux P, Mufti GJ, Hellstr\u00f6m-Lindberg E, et al. Azacitidine prolongs overall survival compared with conventional care regimens in older adult patients with low bone marrow blast count (20\u201330%) acute myeloid leukemia. J Clin Oncol. 2009;28:562\u2013569.","journal-title":"J Clin Oncol"},{"key":"109_CR11","doi-asserted-by":"crossref","unstructured":"Th\u00e9pot S, Itzykson R, Seegers V, et al. Azacytidine (AZA) as first line therapy in AML: results of the French ATU program. Blood (ASH Annual Meeting Abstracts). 2009;114. Abstract 843.","DOI":"10.1182\/blood.V114.22.843.843"},{"key":"109_CR12","doi-asserted-by":"crossref","unstructured":"Itzykson R, Th\u00e9pot S, Recher C, et al. Azacytidine in refractory or relapsed AML after intensive chemotherapy (IC): results of the French ATU program. Blood (ASH Annual Meeting Abstracts). 2009;114. Abstract 1054.","DOI":"10.1182\/blood.V114.22.1054.1054"},{"key":"109_CR13","doi-asserted-by":"crossref","unstructured":"Gr\u00f6vdal M, Khan R, Aggerholm A, et al. Maintenance treatment with 5-azacitidine for patients with high risk myelodysplastic syndrome (MDS) or acute myeloid leukemia following MDS (MDSAML) in complete remission (CR) after induction chemotherapy. Blood (ASH Annual Meeting Abstracts). 2008;112. Abstract 2 223.","DOI":"10.1182\/blood.V112.11.223.223"},{"key":"109_CR14","doi-asserted-by":"crossref","unstructured":"Gardin C, Pr\u00e9bet T, Bouabdallah K, et al. A phase II study of post-remission therapy with azacitidine (AZA) in patients with AML post-MDS and highrisk MDS: a GFM group study. Blood (ASH Annual Meeting Abstracts). 2009;114. Abstract 844.","DOI":"10.1182\/blood.V114.22.844.844"},{"key":"109_CR15","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1182\/blood-2007-03-078576","volume":"110","author":"A.O. Soriano","year":"2007","unstructured":"Soriano AO, Yang H, Faderl S, et al. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood. 2007;110:2302\u20132308.","journal-title":"Blood"},{"key":"109_CR16","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1080\/10428190802451254","volume":"49","author":"S. Nand","year":"2008","unstructured":"Nand S, Godwin J, Smith S, et al. Hydroxyurea, azacitidine and gemtuzumab ozogamicin therapy in patients with previously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: results from a pilot trial. Leuk Lymphoma. 2008;49:2141\u20132147","journal-title":"Leuk Lymphoma"},{"key":"109_CR17","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1002\/cncr.23789","volume":"113","author":"A. Raza","year":"2008","unstructured":"Raza A, Mehdi M, Mumtaz M, Ali F, Lascher S, Galili N. Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia. Cancer. 2008;113:1596\u20131604.","journal-title":"Cancer"},{"key":"109_CR18","doi-asserted-by":"crossref","unstructured":"Silverman LR, Verma A, Odchimar-Reissig R, et al. A phase I\/II study of vorinostat, an oral histone deacetylase inhibitor, in combination with azacitidine in patients with the myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Initial results of the phase I trial: a New York cancer consortium. J Clin Oncol. 2008;26(suppl.). Abstract 7000.","DOI":"10.1200\/jco.2008.26.15_suppl.7000"},{"key":"109_CR19","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/bmt.2009.134","volume":"45","author":"R. Itzykson","year":"2010","unstructured":"Itzykson R, Th\u00e9pot S, Quesnel B, et al. 5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2010;45:255\u2013260.","journal-title":"Bone Marrow Transplant."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-010-0109-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-010-0109-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-010-0109-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T13:58:56Z","timestamp":1592402336000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-010-0109-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3]]},"references-count":19,"journal-issue":{"issue":"S3","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["109"],"URL":"https:\/\/doi.org\/10.1007\/s12325-010-0109-3","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,3]]}}}